PharmaTimes March 24, 2025
Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants
The World Health Organization (WHO) has announced that it has added Pfizer’s maternal respiratory syncytial virus (RSV) vaccine to its list of prequalified vaccines.
Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated lower respiratory tract disease in infants during the first six months through the transfer of antibodies during gestation.
RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people can recover within a week or two, the virus can cause severe illness in certain groups, including infants.
There are currently no specific treatments for RSV infection, underscoring the importance of preventive measures such...
Today's Sponsors
Today's Sponsor